Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Diflucan Generic Delayed Until July, Court Affirms

This article was originally published in The Pink Sheet Daily

Executive Summary

Ranbaxy's ANDAs for Diflucan may not be approved until Pfizer's pediatric exclusivity expires in July, a federal appeals court ruled

You may also be interested in...



Diflucan Generics Launch Following Expiration Of Pfizer Exclusivity

FDA approves numerous ANDAs for tablet, oral suspension and injectable forms of the antifungal upon expiration of Diflucan's six-month pediatric extension. Pfizer is marketing its own generic through its Greenstone subsidiary.

Diflucan Generics Launch Following Expiration Of Pfizer Exclusivity

FDA approves numerous ANDAs for tablet, oral suspension and injectable forms of the antifungal upon expiration of Diflucan's six-month pediatric extension. Pfizer is marketing its own generic through its Greenstone subsidiary.

Ranbaxy Diflucan Generic Launch Delayed Until July Under Court Ruling

Company's fluconazole ANDAs are subject to the six-month pediatric extension for Pfizer's patent on the antifungal, a federal court says.

Related Content

Topics

UsernamePublicRestriction

Register

PS059292

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel